DRL enters agreement to sell its rights to anti-cancer agent E7777 to Citius Pharma
Dr Reddy’s Laboratories Ltd announced that it has entered into a definitive agreement with Citius Pharmaceuticals, Inc. pursuant to which it sold... Read More
DCGI – India approved anti-Covid drug 2-DG developed by DRDO for emergency use
The Drugs Controller General of India has approved an anti-COVID-19 drug developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS)... Read More
DRL sells brand Sernivo; grants Promiseb and Trianex US marketing rights to Encore Dermatology
Posted on03 Apr 2019
Comments0
Dr. Reddy’s Laboratories Limited through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for Sernivo (betamethasone dipropionate)... Read More
Dr. Reddy’s sells Cloderm cream to EPI Health
Posted on03 Oct 2018
Comments0
Dr. Reddy’s Laboratories’ wholly owned U.S. subsidiary Promius Pharma has sold rights of Cloderm (clocortolone pivalate) cream and its authorised generic to... Read More
Case Study: Dr. Reddy’s Out-Licensing deal Of DFD-06 To Encore Dermatology
Dr. Reddy’s Laboratories Ltd., through its wholly owned subsidiary Promius Pharma, LLC announced that it has out-licensed the future development, manufacturing, and... Read More
DRL launches generic sofosbuvir & velpatasvir tablets for HCV in India
Posted on15 May 2017
TagsDr. Reddy’s Laboratories, DRL, Sofosbuvir, sofosbuvir & velpatasvir tablets, sofosbuvir/velpatasvir/voxilaprevir
Comments0
Dr Reddy’s Laboratories has launched the generic version of sofosbuvir 400mg and velpatasvir 100mg fixed-dose combination, indicated for the treatment of chronic... Read More
DRL to market and distribute Amgen’s Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India
Dr Reddy’s Laboratories (DRL) has expanded its strategic collaboration with US-based independent biotechnology firm Amgen to market and distribute in India three... Read More
DRL’s Purple Health Initiative: Packaging Innovation to improve patient compliance
In an effort to improve patient compliance and provide them support services, Dr Reddy’s Laboratories has rolled out its Purple Health initiative... Read More
DRL to enhance ANDA portfolio with acquisition of 8 ANDA from Teva
Dr. Reddy’s Laboratories has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. and an affiliate of Allergan plc to acquire... Read More
DRL acquired 6 OTC brands from Ducere Pharma in US
Dr. Reddy’s Laboratories Ltd has acquired a portfolio of half a dozen over-the-counter (OTC) drug brands from American drugmaker Ducere Pharma to... Read More